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Patients with myeloid neoplasms with eosinophilia, and the FIP1L1-PDGFRA fusion gene, are exquisitely sensitive to imatinib and many of them reach a durable molecular remission under imatinib. 2, 3 Yet, rare cases of secondary resistance have also been reported, with the acquisition of a T674I mutation in seven patients and a D842V mutation in one (for a recent overview, see Metzgeroth et al. 4 ). 3 --5 The FIP1L1-PDGFRA-T674I mutation has limited to absent sensitivity to nilotinib and dasatinib in vitro but responds well to sorafenib. 6, 7 However, the effect of sorafenib in two patients with the FIP1L1-PDGFRA-T674I mutation was limited and variable: no response was obtained in one case, whereas in the other patient, a short-lived response was followed by selection of the panresistant FIP1L1-PDGFRA-D842V mutation and blast crisis. 4, 7 Myeloid/lymphoid neoplasms associated with eosinophilia and a rearrangement of FGFR1, also known as the 8p11 myeloproliferative syndrome (EMS), are aggressive stem cell disorders. 8 Although, the FGFR1 fusion kinase constitutes a potential therapeutic target, the disease remains medically untreatable today. Finally, various KIT mutations are pathogenic drivers in gastrointestinal stromal tumors (GIST), systemic mastocytosis (SM) and other malignancies. The KIT-D816V mutation occurs in SM and melanoma and is primarily resistant to imatinib. In GIST, KIT-W557_K558del mutations are common and respond well to imatinib treatment, but here also different secondary mutations (T670I and D820A) are known that confer resistance. 9 Besides its activity against BCR-ABL1, the activity of ponatinib in vitro also encompasses PDGFRA, KIT and FGFR1. 1 Potent activity towards oncogenic fusion or mutant kinases such as FIP1L1-PDGFRA, KIT-N822K and FGFR1OP2-FGFR1 has also been documented. 10 Therefore, we investigated the effect of ponatinib on imatinib-resistant mutations of FIP1L1-PDGFRA, of KIT and on an imatinib-insensitive FGFR1 fusion.
Ba/F3 cells expressing the imatinib-resistant FIP1L1-PDGFRA-T674I or panresistant FIP1L1-PDGFRA-D842V mutant were cultured for 24 h in the presence of increasing ponatinib concentrations. Ponatinib strongly inhibited growth of the FIP1L1-PDGFRA-T674I mutant-expressing cells with an IC50 of 9 nM. It was also active against the FIP1L1-PDGFRA-D842V mutant but with a higher IC50 (154 nM) (Figure 1a ). The IC50 of ponatinib for BCR-ABL1-T315I-and FIP1L1-PDGFRA-expressing Ba/F3 was 16 nM and 0.6 nM, respectively, consistent with previous reports (data not shown).
1,10 IL-3-driven growth of wild-type Ba/F3 cells was highly resistant to ponatinib (IC50 of 2 mM) (Figure 1a) . With western blotting, we demonstrate a strong inhibition of the constitutive autophosphorylation of either FIP1L1-PDGFRA-T674I or FIP1L1-PDGFRA-D842V by ponatinib starting from 10 nM and 500 nM, respectively. Also, the FIP1L1-PDGFRA downstream targets STAT5 and ERK1/2 were inactivated at similar concentrations ( Figure 1b) . Next, we explored the activity of ponatinib against CUX1-FGFR1, a recently described oncogenic FGFR1 fusion kinase, not responding to imatinib. 11 The growth of CUX1-FGFR1-expressing Ba/F3 cells was inhibited by ponatinib with an IC50 of 56 nM (Figure 1c) . Again, this correlated nicely with decreasing tyrosine phosphorylation of the fusion protein and its downstream targets STAT5 and ERK1/2 ( Figure 1d ).
Furthermore, we investigated cell-based models of imatinibresistant KIT mutant-driven malignancies. Ba/F3 cells were used expressing KIT-D816V, KIT-Y823D, KIT-W557_K558del þ T670I and KIT-W557_K558del þ D820A. Treatment for 24 h with increasing ponatinib concentrations strongly inhibited cell growth of Ba/F3 cells expressing the KIT double mutants KIT-W557_K558del þ T670I and KIT-W557_K558del þ D820A with an IC50 of 15 nM and 2 nM, respectively. For the primary imatinib-resistant KIT mutants, an IC50 of 62 nM (KIT-Y823D) and 405 nM (KIT-D816 V) was recorded (Figure 2a) . With western blotting, a complete inhibition of KIT phosphorylation was demonstrated for the KIT double mutants upon ponatinib treatment at 100 nM, with a corresponding decreasing phosphorylation of the downstream targets ERK1/2 and AKT (Figure 2b ). Although KIT-Y823D phosphorylation was sensitive to ponatinib, this was less the case for its downstreamsignaling intermediates ERK1/2 and AKT (Figure 2b ). In line with the growth experiment, ponatinib had no effect on KIT-D816V phosphorylation (data not shown).
Thus, ponatinib is highly active in vitro towards the major imatinib-resistant FIP1L1-PDGFRA-T674I mutation and, at the higher end of the clinically achievable concentration range, against FIP1L1-PDGFRA-D842V. 12 Although the number of eligible patients is low, their prognosis is uniformly dismal, which urges clinical testing of ponatinib in this setting. 4 We also demonstrate strong inhibition of the CUX1-FGFR1 fusion by ponatinib at clinically achievable levels. This provides additional credence to its activity against FGFR1-derived oncogenic fusions in cell lines. 10 Of interest, we previously showed sensitivity of the CUX1-FGFR1 fusion to dovitinib, but with ponatinib the non-toxic range is broader. 11 Taken together, this suggests that ponatinib could have a wider therapeutic index than dovitinib in the treatment of EMS. Lastly, the inhibitory potential of ponatinib was evaluated for different imatinib-resistant KIT mutants. The imatinib-resistant double mutant KIT-W557_K558del þ T670I was shown to be sensitive to sunitinib and sorafenib, whereas KIT-W557_K558del þ D820A was not previously investigated. 13, 14 Here, we demonstrate a good response of both mutants to low nanomolar doses of ponatinib, and in this context ponatinib adds to the diversity of treatment options. Also the primary imatinib-resistant KIT-Y823D mutant, known to be sensitive to sorafenib, was inhibited by ponatinib. In contrast, ponatinib lacks therapeutic efficacy towards the imatinib-resistant KIT-D816V mutation, typically occurring in SM. Ponatinib is a type-II inhibitor targeting the inactive DFG-out conformation of the kinase. 15 The KIT-D816V mutation alters the inactive --active equilibrium by stabilizing the activated kinase conformation. Thus, binding of type-II inhibitors, such as ponatinib, is hindered leading to a reduced inhibitory activity. 12, 15 In summary, our data indicate that ponatinib, which is currently under investigation in phase II clinical trials for imatinib-resistant CML, is active in vitro against CUX1-FGFR1, FIP1L1-PDGFRA-T674I, FIP1L1-PDGFRA-D842V and against specific KIT mutants. Its potential in the therapeutic management of EMS, primary or secondary imatinib-resistant GIST, or imatinib-resistant FIP1L1-PDGFRA-positive disease, needs further evaluation. the 5q-syndrome, more frequently found in old-aged females, is characterized by erythroid hypoplasia, macrocytic anemia, normal to elevated platelets count, preponderance of monolobulated megakaryocytes, isolated 5q deletion and low rate of progression to AML. Now, the 5q-syndrome is recognized as a clinical and biological entity of MDS according to the revised World Health Organization (WHO) classification in 2008. 2 The WHO classification recognized that the 5q-syndrome is narrowly defined as de novo MDS with an isolated cytogenetic abnormality involving deletions between bands q21 and q32 of chromosome 5. The criteria for inclusion have evolved from the description by Van den Berghe et al.
1 to normal to increased megakaryocytes with hypolobated nuclei, o5% blasts, no Auer rods in bone marrow and normal or increased platelets and o5% blasts in blood. Furthermore, additional cytogenetic abnormalities or 5% or more blasts in the blood or marrow is exclusionary for the diagnosis. 2 Therefore, most of the patients (95%) with an isolated 5q deletion do not fit the WHO criteria to be included in this subset of MDS, which appears to be rare. 3, 4 For over 15 years, many studies have focused on defining the common deleted region of chromosome 5.
5 --10 Initially, the Knudson two-hit model was thought to occur in these large deletions. Now, the haploinsufficiency of one or more genes seems the model to explain 5q deletion consequences.
11
In this work, our objective was to characterize breakpoints of del(5q) among 70 MDS and 24 AML patients using fluorescence in situ hybridization (FISH). We identified not only the common deleted region but also the common retained regions in these 94 MDS/AML patients. We differentiated patients with isolated 5q deletion and those with additional chromosomal abnormalities.
Patients were distributed in two groups (Supplementary Table) . Group 1 consisted of patients with an apparently isolated del(5q) (46 patients: 42 MDS and 4 AML). In this group, we integrated five patients with MDS associated with isolated del(5q), according to the criteria of the revised WHO classification (bone marrow: normal to increased megakaryocytes with hypolobated nuclei, o5% blasts, no Auer rods; blood: platelets normal or increased, o5% blasts) (I25-I29). Group 2 included patients with del(5q) and additional cytogenetic abnormalities (48 patients: 28 MDS and 20
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